Marvel Biosciences Selects CMAX as MB-204 Phase I Trial Site
Marvel Biosciences said MB-204 is advancing toward first-in-human testing and selected CMAX as the site for its Phase I clinical trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.